Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
DT-2216 by Dialectic Therapeutics for Solid Tumor: Likelihood of Approval
DT-2216 is under clinical development by Dialectic Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Data Insights
DT-2216 by Dialectic Therapeutics for Blood Cancer: Likelihood of Approval
DT-2216 is under clinical development by Dialectic Therapeutics and currently in Phase I for Blood Cancer. According to GlobalData, Phase...